Elite Pharmaceuticals Inc (ELTP)

Name: Elite Pharmaceuticals Inc Financial Statements
Creator: Quarter Results

Healthcare | Drug Manufacturers Specialty Generic

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$31.6M

Net Income

$18.6M

Operating Margin

28.5%

Free Cash Flow

$4.9M

Debt / Assets

44.5%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Elite Pharmaceuticals Inc (ELTP).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2024-12-31
Revenue	31,589,251	36,321,704	40,211,097	14,364,248
Cost of Revenue	18,636,076	22,248,671	12,985,127	8,244,907
Gross Profit	12,953,175	14,073,033	27,225,970	6,119,341
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	2,466,336	4,029,199	3,456,413	2,724,616
Operating Expenses	3,940,232	5,859,287	5,526,263	5,021,531
Operating Income	9,012,943	8,213,746	21,699,707	1,097,810
Interest Expense	80,204	82,470	158,926	77,607
Income Before Tax	20,833,716	15,690,347	-564,214	-10,652,765
Income Tax Expense	2,239,910	1,987,940	5,320,501	239,175
Net Income	18,593,806	13,702,407	-5,884,715	-10,891,940
Per Share
EPS	0.02	0.01	-0.01	-0.01
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Elite Pharmaceuticals Inc (ELTP).
Income Statement (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Revenue	84,043,929	56,625,128	34,155,114,000	32,262,117	25,380,749
Cost of Revenue	43,957,274	30,268,025	17,561,093,000	17,466,763	13,513,611
Gross Profit	40,086,655	26,357,103	16,594,021,000	14,795,354	11,867,138
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	9,229,495	7,305,035	5,122,272,000	4,478,356	3,336,226
Operating Expenses	20,486,187	15,568,334	12,918,019,000	9,724,644	9,762,615
Operating Income	19,600,468	10,788,769	2,025,111,000	5,070,710	2,104,523
Interest Expense	772,367	588,622	1,112,707	191,816	259,598
Income Before Tax	-52,140	463,092	3,985,874,000	6,304,429	4,144,514
Income Tax Expense	4,262,519	-19,645,539	-424,028,000	-1,736,437	-943,907
Net Income	-4,314,659	20,108,631	4,409,902,000	8,898,245	5,088,421
Per Share
EPS	0.00	0.02	4.35	0.01	0.01
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Elite Pharmaceuticals Inc (ELTP).
Balance Sheet (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Assets
Cash and Cash Equivalents	11,315,385	7,106,262	7,832,247	8,535,357
Short Term Investments	0	0	0	0
Net Receivables	29,207,028	19,453,301	3,094,549	3,057,913
Inventory	16,240,376	12,930,464	9,550,716	6,741,170
Total Current Assets	57,739,147	40,014,189	21,510,297	18,861,389
Property Plant Equipment	14,099,023	14,610,152	10,439,220	6,984,876
Goodwill and Intangibles	5,637,802	6,341,228	6,341,228	6,634,035
Total Assets	96,387,477	83,653,536	40,896,018	35,148,898
Liabilities
Account Payables	2,957,584	2,714,306	2,446,810	1,430,985
Short Term Debt	5,082,068	5,020,378	325,768	556,781
Total Current Liabilities	11,840,435	13,049,764	7,833,637	6,694,241
Long Term Debt	5,832,820	6,717,390	3,561,520	2,224,787
Total Liabilities	42,872,448	26,070,718	11,935,758	9,926,871
Shareholders Equity
Retained Earnings	-120,703,926	-116,389,267	-136,497,898	-140,059,744
Total Shareholders Equity	53,515,029	57,582,818	28,960,260	25,222,027

Balance sheet annual history for Elite Pharmaceuticals Inc (ELTP).
Balance Sheet (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Assets
Cash and Cash Equivalents	11,315,385	7,106,262	7,832,247	8,535,357	3,192,768
Short Term Investments	0	0	0	0	0
Net Receivables	29,207,028	19,453,301	3,094,549	3,057,913	3,496,376
Inventory	16,240,376	12,930,464	9,550,716	6,741,170	5,012,902
Total Current Assets	57,739,147	40,014,189	21,510,297	18,861,389	12,194,667
Property Plant Equipment	14,099,023	14,610,152	10,439,220	6,984,876	6,864,039
Goodwill and Intangibles	5,637,802	6,341,228	6,341,228	6,634,035	6,634,035
Total Assets	96,387,477	83,653,536	40,896,018	35,148,898	26,189,492
Liabilities
Account Payables	2,957,584	2,714,306	2,446,810	1,430,985	929,690
Short Term Debt	5,082,068	5,020,378	325,768	556,781	598,908
Total Current Liabilities	11,840,435	13,049,764	7,833,637	6,694,241	5,812,531
Long Term Debt	5,832,820	6,717,390	3,561,520	2,224,787	1,779,600
Total Liabilities	42,872,448	26,070,718	11,935,758	9,926,871	10,037,563
Shareholders Equity
Retained Earnings	-120,703,926	-116,389,267	-136,497,898	-140,059,744	-148,957,989
Total Shareholders Equity	53,515,029	57,582,818	28,960,260	25,222,027	16,151,929

Cash flow quarterly history for Elite Pharmaceuticals Inc (ELTP).
Cash Flow Statement (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Operating Activities
Net Income	-4,314,659	20,108,631	3,561,846	8,898,245
Depreciation & Amortization	2,122,343	1,471,584	1,344,683	1,434,709
Stock Based Compensation	227,565	8,513,927	579,325	781,475
Change in Working Capital	-15,166,285	-11,880,605	-2,025,634	-1,010,037
Operating Cash Flow	7,455,639	-3,281,558	3,338,704	6,508,314
Investing Activities
Capital Expenditure	-2,525,082	-809,653	-5,736,618	-498,566
Investments	-1,625,082	-809,653	-5,736,618	-498,566
Investing Cash Flow	-2,399,832	-809,653	-5,736,618	-498,566
Financing Activities
Debt Repayment	-845,045	3,339,181	-12,736,786	-667,133
Common Stock Issued/Repurchased	19,305	159,921,000	39,325,000	14,353,000
Dividends Paid	0	0	0	0
Financing Cash Flow	-825,740	3,385,624	1,702,199	-667,133
Summary
Free Cash Flow	4,930,557	-4,091,211	-2,397,914	6,009,748
Net Change in Cash	4,230,067	-705,587	-695,715	5,342,615

Cash flow annual history for Elite Pharmaceuticals Inc (ELTP).
Cash Flow Statement (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Operating Activities
Net Income	-4,314,659	20,108,631	3,561,846	8,898,245	5,088,421
Depreciation & Amortization	2,122,343	1,471,584	1,344,683	1,434,709	1,524,591
Stock Based Compensation	227,565	8,513,927	579,325	781,475	935,624
Change in Working Capital	-15,166,285	-11,880,605	-2,025,634	-1,010,037	-2,057,886
Operating Cash Flow	7,455,639	-3,281,558	3,338,704	6,508,314	3,193,861
Investing Activities
Capital Expenditure	-2,525,082	-809,653	-5,736,618	-498,566	-329,981
Investments	-1,625,082	-809,653	-5,736,618	-498,566	-329,981
Investing Cash Flow	-2,399,832	-809,653	-5,736,618	-498,566	-262,781
Financing Activities
Debt Repayment	-845,045	3,339,181	-12,736,786	-667,133	-1,925,532
Common Stock Issued/Repurchased	19,305	159,921,000	39,325,000	14,353,000	42,223
Dividends Paid	0	0	0	0	0
Financing Cash Flow	-825,740	3,385,624	1,702,199	-667,133	-869,829
Summary
Free Cash Flow	4,930,557	-4,091,211	-2,397,914	6,009,748	2,863,880
Net Change in Cash	4,230,067	-705,587	-695,715	5,342,615	2,061,251